Celsion’s GEN-1 Shows Promise in Newly-diagnosed Advanced Ovarian Cancer Patients

Celsion’s GEN-1 Shows Promise in Newly-diagnosed Advanced Ovarian Cancer Patients
All ovarian cancer patients treated in the Phase 1b OVATION trial benefited from the combination of Celsion's GEN-1 with standard of care. The trial enrolled advanced ovarian cancer patients who never had been treated. Among them, 100 percent had at least stable disease, and 86 percent saw a reduction or complete elimination of their tumors after receiving GEN-1 plus chemotherapy. The responses correlated with successful surgical resections, which improved outcomes in the long run. At this point, the time to disease progression or death is 18 months in the trial's participants, which compares favorably to the 12 months seen in historical control subjects. These were the latest findings from the trial, which were featured in a poster presentation at the American Association of Cancer Research (AACR)'s special conference “Addressing Critical Questions in Ovarian Cancer Research and Treatment” held in Pittsburgh, Pennsylvania. The poster, "Immunological changes following intraperitoneal administration of a formulated IL-12 plasmid in combination with neoadjuvant chemotherapy in newly diagnosed advanced ovarian cancer patients," also showed that intraperitoneal GEN-1, together with chemotherapy, enhanced anti-tumor immune responses in the tumor. GEN-1 is a nanoparticle that contains the DNA sequence for the pro-inflammatory protein interleukin-12 (IL-12). GEN-1 triggers a sustained production and rele
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *